LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Novocure Ltd

Abierto

SectorSanidad

17.56 -1.24

Resumen

Variación precio

24h

Actual

Mínimo

17.43

Máximo

18.27

Métricas clave

By Trading Economics

Ingresos

-47M

-71M

Ventas

-295K

174M

BPA

-0.62

Margen de beneficios

-40.871

Empleados

1,605

EBITDA

-29M

-63M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+46.23% upside

Dividendos

By Acuity

Próximas Ganancias

23 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

506M

2B

Apertura anterior

18.8

Cierre anterior

17.56

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

146 / 342 Clasificación en Healthcare

Novocure Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Acerca de Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat